Status:
UNKNOWN
AI-Assisted Insulin Titration System on Inpatients Glucose Control
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
This is a multi-center, open-labeled, parallel group, randomized controlled trial to access the effect and safety of the Artificial Intelligence Assisted Insulin Titration System (iNCDSS) in patients ...
Detailed Description
As one of the most common treatments for diabetes inpatients, insulin regimens often vary due to different physicians. Since 2016, Zhongshan Hospital has set up the Internet-based glucose management s...
Eligibility Criteria
Inclusion
- Men or women aged 18-99 years old;
- Inpatients who had been diagnosed with type 2 diabetes;
- Subjects who are on treatment with insulin for at least 3 months;
- HbA1c: 7.0%-10.0%.
Exclusion
- Patients who were diagnosed with T1D, gestational diabetes or other specific types of diabetes.
- Subjects with acute complications of diabetes such as ketoacidosis or hyperglycemic hyperosmolar state;
- Patients with severe cardiac, hepatic, renal or general diseases;
- Subjects that are, in the judgement of the investigator, unlikely to comply with the protocol.
- Absence of informed consent.
Key Trial Info
Start Date :
November 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04517201
Start Date
November 4 2020
End Date
December 1 2021
Last Update
March 23 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital
Shanghai, Shanghai Municipality, China, 200032
2
Zhongshan Hospital, Fudan University
Shanghai, China